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Abstract
Background: MicroRNAs are a class of small noncoding RNAs that are abnormally expressed in different cancer cells. 
Molecular signature of miRNAs in different malignancies suggests that these are not only actively involved in the 
pathogenesis of human cancer but also have a significant role in patients survival. The differential expression patterns 
of specific miRNAs in a specific cancer tissue type have been reported in hundreds of research articles. However limited 
attempt has been made to collate this multitude of information and obtain a global perspective of miRNA 
dysregulation in multiple cancer types.
Results: In this article a cancer-miRNA network is developed by mining the literature of experimentally verified cancer-
miRNA relationships. This network throws up several new and interesting biological insights which were not evident in 
individual experiments, but become evident when studied in the global perspective. From the network a number of 
cancer-miRNA modules have been identified based on a computational approach to mine associations between cancer 
types and miRNAs. The modules that are generated based on these association are found to have a number of 
common predicted target onco/tumor suppressor genes. This suggests a combinatorial effect of the module 
associated miRNAs on target gene regulation in selective cancer tissues or cell lines. Moreover, neighboring miRNAs 
(group of miRNAs that are located within 50 kb of genomic location) of these modules show similar dysregulation 
patterns suggesting common regulatory pathway. Besides this, neighboring miRNAs may also show a similar 
dysregulation patterns (differentially coexpressed) in the cancer tissues. In this study, we found that in 67% of the 
cancer types have at least two neighboring miRNAs showing downregulation which is statistically significant (P < 10-7, 
Randomization test). A similar result is obtained for the neighboring miRNAs showing upregulation in specific cancer 
type. These results elucidate the fact that the neighboring miRNAs might be differentially coexpressed in cancer tissues 
as that of the normal tissue types. Additionally, cancer-miRNA network efficiently detect hub miRNAs dysregulated in 
many cancer types and identify cancer specific miRNAs. Depending on the expression patterns, it is possible to identify 
those hubs that have strong oncogenic or tumor suppressor characteristics.
Conclusions: Limited work has been done towards revealing the fact that a number of miRNAs can control commonly 
altered regulatory pathways. However, this becomes immediately evident by accompanying the analysis of cancer-
miRNA relationships in the proposed network model. These raise many unaddressed issues in miRNA research that 
have never been reported previously. These observations are expected to have an intense implication in cancer and 
may be useful for further research.
Background
A family of approximately 22 nucleotide (nt) noncoding
RNAs termed microRNAs (miRNAs) has been identified
in eukaryotic organisms ranging from nematodes to
humans [1-3]. Caenorhabditis elegans (C. elegans) lin-4
and let-7 are the first discovered miRNAs [4-6]. Increas-
ing evidence indicates that miRNAs are key regulators of
various fundamental biological processes such as prolif-
eration, apoptosis, differentiation, and so on [7]. For
example let-7 family miRNAs identified in C. elegans,
Drosophila, Zebrafish or Human [5,8,9] have important
roles for terminal differentiation in normal embryonic
development, temporal upregulation and so on. In let-7
mutants, stem cells can fail to exit the cell cycle and ter- * Correspondence: sanghami@isical.ac.in
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minally differentiate at the correct time [5], so that they
continue to divide which is an indication of cancer.
MiRNA genes are transcribed by RNA polymerase II
(Pol II) in the nucleus to form large pri-miRNA tran-
scripts which are capped (7MGpppG) and polyadenylated
(AAAAA). These pri-miRNA transcripts are processed
by the RNase III enzyme Drosha and its cofactor,
DGCR8, to release an approximately 70-nucleotide pre-
miRNA precursor product. RAN-GTP and exportin 5
transport this pre-miRNA into the cytoplasm [10,11].
Subsequently, another RNase III enzyme, Dicer, cleaves
the pre-miRNA in the cytoplasm about two helical turns
away from the ends of the pre-miRNA stem loop, produc-
i n g  a  d o u b l e  s t r a n d e d  R N A .  A  h e l i c a s e  u n w i n d s  t h e
cleaved double stranded RNA in a strand specific direc-
tion. One of the unwound strands is subsequently incor-
porated into a ribonuclear particle complex, RNA-
induced silencing complex (RISC) [12,13] and the other
one (miRNA*) is degraded. The choice of the strand relies
on the local thermodynamic stability of the miRNA/
miRNA* duplex. The strand whose 5' end is less stably
paired is loaded into the RISC. The mature miRNA then
regulate gene expression by inhibiting translation and/or
by inducing degradation of target messenger RNAs [14-
17]. According to the miRBase of Sanger Institute http://
microRNA.sanger.ac.uk/ approximately 700 miRNAs are
found in human and up to one third of the total human
mRNAs are predicted to be miRNA targets. Each miRNA
can target approximately 200 transcripts directly or indi-
rectly, whereas more than one miRNA can converge on a
single protein coding gene target.
Recent studies indicate that many miRNAs, referred to
as onco/tumor suppressor miRNAs, are involved in the
development of various human malignancies [18-21].
Aberrant expression of miRNAs contributes to carcino-
genesis by promoting the expression of proto oncogenes
or by inhibiting the expression of tumor suppressor genes
[22-26]. For example, miR-143 and miR-145 are downreg-
ulated in colon cancer [27], miR-127 is down regulated or
silenced in T24 cell (Bladder transitional carcinoma cell);
on the otherhand miR-99 is overexpressed/amplified in
pancreatic cancer. In the following sections an extensive
review of the involvement of different miRNAs in various
cancer types is first conducted and the role of miRNAs in
patients survival is then elucidated.
Involvement of miRNA in human cancer
It has been observed that about 50% of miRNA genes are
localized in cancer associated genomic regions (CAGR)
or fragile sites [23] as well as in minimal regions of loss of
heterozygosity, minimal regions of amplification, or com-
mon breakpoint regions. Consideration of fragile sites is
important as these are preferential sites of translocation,
deletion, amplification, or integration of exogenous
genome. MiRNAs located near fragile site could be possi-
ble targets of such genomic alterations. For example miR-
15a and miR-16-1 are located at chromosome 13q14.2, a
region that is known to be fragile. In fact these genes are
found to be downregulated or deleted in a significant
fraction of patients with B cell Chronic Lymphocytic Leu-
kaemia (B-CLL), prostate cancer, mantle cell lymphoma
and multiple myeloma [28]. It is an evidence that one or
more tumor suppressor miRNAs at 13q14.2 are involved
in the pathogenesis of these human cancers [29].
In various cancer malignancies approximately 200 miR-
NAs have been identified which are dysregulated signifi-
cantly. Evidence of the involvement of such miRNAs,
their implications to cancer through targeting proto
oncogenes or tumor suppressor genes have been
described in the following subsections.
Lung cancer
Lung cancer is a disease in which the cells of lung tissues
grow uncontrollably and form tumors. Loss or amplifica-
tion of a number of miRNAs have been found related to
lung cancer. A differential expression pattern of a number
of miRNAs has been found in lung cancer tissues than
normal lung tissues of which approximately 30% of the
miRNAs are located within exons or introns of known
protein coding genes [30]. In an in vitro experiment it has
been revealed that downregulation of let-7 family in
human upregulates RAS protein resulting in lung cancer
[31]. In this article we have reported that a total of 64
miRNAs are differentially expressed in lung cancer
among which 44 are downregulated or deleted (see Addi-
tional file 1).
Leukemia--acute lymphoblastic, acute myeloid and chronic 
lymphocytic
One of the most common childhood cancer type is acute
lymphoblastic leukemia (ALL) derived from the clonal
proliferation of lymphoid progenitors in the bone mar-
row. Acute myeloid leukemia (AML) is a heterogeneous
group of genetically diverse hematopoietic malignancies
where frequent translocations of chromosomes are
observed in general. Chronic lymphocytic leukemia
(CLL) is characterized by the gradual accumulation of
small mature B-cells, non proliferating cells and B-cell
surface markers such as CD19, CD20 in addition to CD5
[32] in the patient. In recent years a number of miRNAs
are reported to be involved in various types of leukemia.
The five most highly expressed miRNAs in ALL reported
in [32] are miR-128b, miR-204, miR-218, miR-331, and
miR-181b-1. In CLL, the five most highly expressed miR-
NAs are miR-331, miR-29a, miR-195, miR-34a, and miR-
29c. Among these, miR-331 is also overexpressed in ALL.
Another miRNA, miR-29a is clustered with miR-29b-1.
In [33], this cluster is identified as a hematopoietic-Bandyopadhyay et al. Silence 2010, 1:6
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enriched cluster in human acute T-cell leukemia and
human megakaryoblastic leukemia cell lines. The two
miRNAs, miR-15a and miR-16-1 are located at chromo-
somal location 13q14.3 that is deleted in B-CLL [23]. In
[34], it has been shown that miR-181a family miRNAs are
expressed at relatively low levels in AML. In another
experiment, it has been revealed that miR-23b is
repressed and miR-221, miR-222 and miR-34a are signifi-
cantly upregulated in AML specimens compared to nor-
mal bone marrow and CD34+ haematopoietic progenitor
cells [35].
Breast cancer
I n  t h is  a rt i c l e  w e  h a v e  r e po rt ed  t h a t  a p p r o x i m a t e l y  4 0
miRNAs have been found to be dysregulated in breast
cancer (see Additional file 1). Among these, a smaller set
of miRNAs are able to correctly predict normal or tumor-
ous breast tissue with 100% accuracy. In particular, miR-
10b, miR-125b, miR-145, miR-21 and miR-155 emerged
as the ones most consistently dysegulated [22]. MiR-10b,
miR-125b and miR-145 may be acting as tumor suppres-
sor miRNAs and are downregulated in breast cancer
cells, while the remaining two are upregulated. This sug-
gests that these miRNAs may be potentially acting as
onco/tumor suppressor miRNAs. It is hypothesized that
the miRNAs downregulated in tumor tissues might be
targeting oncogenes. In fact the putative targets of miR-
10b are genes such as FLT1, the v-crk homologue the
growth factor BDNF and the transducing factor SHC1,
and so on. These genes are known to have oncogenic
functions. For miR-125b, some target genes which have
potential oncogenic functions are YES, ETS1, TEL,
AKT3, the growth factor receptor FGFR2 and members
of the mitogen activated signal transduction pathway
VTS58635, MAP3K10, MAP3K11, MAPK14, and so on.
For miR-145, some of the predicted target oncogenes are
MYCN, FOS, YES, FLI1, MAPK transduction proteins
such as MAP3K3 and MAP4K4, and so on. It is also
hypothesized that the upregulated miRNAs might be tar-
geting tumor suppressor genes. For example potential
targets of miR-155 are the tumor suppressor genes
SOCS1 and APC. It was found that growth inhibition in
breast cancer cell line MCF-7 is possible due to the trans-
fection of anti-miR-21 (chemically modified oligonucle-
otides). Another miRNA miR-9-3 is downregulated in
breast cancer with either high vascular invasion or pres-
ence of lymph node metastasis [22]. A recent experimen-
tal evidence suggests that miR-205 can be considered as a
potential breast tumor suppressor gene that directly tar-
gets HER3 receptor. HER3 overexpression is a hallmark
of a particularly aggressive subset of breast tumors [36].
Pancreatic cancer
Pancreatic cancer is one of the most common cancer type
with a very poor prognosis, partially due to its very low
accessibility to resection and resistance to chemoradio-
therapy [37]. An miRNA based treatment of pancreatic
cancer thereafter appears to be an important alternative
towards cancer therapy as miRNAs can be directed
against pancreatic cancer through various pathways,
including the inhibition of overexpressed oncogenes, sup-
pressor of tumor growth and enhancement of apoptosis.
In our present study we found that, 46 miRNAs are dys-
regulated in pancreatic cancer among which a significant
number of miRNAs are overexpressed (P = 6.639 × 10-13,
for details see Table 1) showing that miRNAs tend to be
upregulated in pancreatic tumor tissue. In [38], it has
been reported that miR-99, miR-100, miR-100-1, miR-
125a, miR-125b-1, miR-199a-1 and miR-199a-2 are over-
expressed both in pancreatic cancer and chronic pancrea-
titis compared with normal pancreatic tissue indicating
that these can be a common inciting event for neoplastic
growth.
Colon cancer
In [27], two mature miRNAs miR-143 and miR-145 are
identified as reduced steady state level at the adenoma-
tous and cancer stages of colorectal neoplasia compared
Table 1: Cancer tissues where significant number of miRNAs are either up or downregulated
Cancer type % of miRNAs Dysregulation patterns P-value()
Brain 94.04% (79/84) Downregulated 7.106 × 10-16
Hematologic 100% (32/32) Downregulated 1.642 × 10-8
Kidney 100% (4/4) Upregulated 3.249 × 10-2
Lymphoma 100% (9/9) Upregulated 4.228 × 10-4
Prostate 83.33% (15/18) Upregulated 4.406 × 10-4
Pancreas 91.30% (42/46) Upregulated 6.639 × 10-13
Stomach/Gastric 90.90% (10/11) Upregulated 1.205 × 10-3
Thyroid 81.81% (9/11) Upregulated 1.117 × 10-2Bandyopadhyay et al. Silence 2010, 1:6
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to normal cell. Recently on the basis of in vivo investiga-
tion [39] it was observed that in the patients group of
complete response, partial response and no change after
chemotherapy the expression level of let-7g is notably
lower than the disease progression group. Based on the
work [39], the hypothesis is that let-7g may be a signifi-
cant indicator for chemo response to 5-FU based antime-
tabolite S-1 based chemotherapy in colon cancer. In the
present study a set of 76 miRNAs are identified that are
differentially expressed in colon tumor tissues or cell
lines.
Prostate cancer
Prostate cancer is the most common form of cancer
among men. Current diagnostic test for prostate cancer is
the prostate specific antigen (PSA) test. PSA test, how-
ever, suffers from high false positive rate. Moreover, after
PSA test is positive a painful and costly biopsy is required
to confirm the presence of cancer. Recently researchers
have begun analyzing the miRNA expression profiles of
normal and tumor samples for the diagnosis of prostate
cancer. In [21], expression profiling revealed that a num-
ber of miRNAs are differentially expressed in prostate
cancer tissues including miR-21. MiR-21 is overexpressed
in various types of cancer indicating that miR-21 is
involved in tumor growth, invasion and metastasis. How-
e v e r ,  t h e  r o l e  o f  m i R - 2 1  i n  p r o s t a t e  c a n c e r  i s  p o o r l y
understood. In [40], the effects of miR-21 on prostate
cancer cell proliferation, apoptosis, and invasion were
examined. The study suggested that miR-21 could pro-
mote apoptosis resistance, motility, and invasion in pros-
tate cancer cells and these effects of miR-21 may be partly
due to its regulation of target genes such as PDCD4,
TPM1, and MARCKS.
Uterine leiomyoma
Uterine (pertaining to the uterus) leiomyoma (ULM) is
the most common neoplasms in women of reproductive
age. Although causes of this disease is still not fully
understood but genetic alterations have been observed.
Near about 40% of ULMs contain simple non random
chromosomal anomalies [41]. Some genes such as estro-
gen receptor α, IGF1, high mobility group genes (HMG)
HMGA1 and HMGA2 and COL4 family members are
implicated in ULM. It is found that these genes have mul-
tiple miRNA target sites in their 3' UTRs [42,43]. In [44] a
distinct miRNA expression profile has been observed
between black and white ULM patients. Mir-23a/b, let-7,
miR-145, miR-197, miR-411 and miR-412 are overex-
pressed in black women ULM patients than white women
ULM patients. The differential expression of miRNAs
between large (≥ 10 cm), medium (4-9 cm) and small (≥ 3
cm) tumor sizes was examined and notably 17 miRNAs
have significant differences based on size of the tumor.
Five miRNAs of the let-7 family are overexpressed in
ULM compared to matched myometrium. Interestingly
higher expression of these miRNAs was also observed in
small ULM than large ULM. It has also been observed
that several miRNAs such as- miR-208, miR-381 and
miR-339 exhibit significant differences by age. In the
present study we have reported a set of 44 miRNAs that
are dysregulated in ULM.
Thyroid cancer
One of the most common cancer in thyroid tissue is pap-
illary thyroid carcinoma. In papillary thyroid carcinoma,
the three strongly overexpressed miRNAs miR-146, miR-
221 and miR-222 have a common target gene KIT. KIT is
an important tyrosine kinase receptor in cell differentia-
tion and growth and its transcript level is known to be
extremely low [45,46]. An interesting observation is that
in some cases miR-221 is not only overexpressed in papil-
lary thyroid tumor tissue but also overexpressed in nor-
mal thyroid tissue which is adjacent to papillary thyroid
carcinoma, suggesting that this might be an important
thyroid cancer marker.
Liver cancer
In [47] a predominant upregulation has been shown for
miR-370, miR-299 and miR-125b which putatively affects
the expression of BAX/AKT, β-catenin, IGF R type I,
respectively. BAX (Bcl2- associated X protein), is a
proapoptosis gene of the Bcl-2 family and it is well known
that proteins of Bcl-2 family are the key regulators of
apoptosis [48-50]. Lower expression of BAX is found in
esophageal squamous cell carcinoma, hepatocellular car-
cinoma (HCC), breast cancer and ovarian cancer [51-54].
Another liver specific miRNA, miR-122, is significantly
down regulated in liver cancer with intrahepatic metasta-
sis. ADAM17 is a gene involved in metastasis is a poten-
tial target of miR-122 [55]. Silencing of ADAM17 by miR-
122 resulted in a dramatic reduction of in vitro migration,
invasion, in vivo tumorigenesis, angiogenesis, and local
invasion. A set of 22 miRNAs are differentially expressed
in HCC reported in our present study (see Additional file
1).
Stomach cancer
Cancer that forms in tissues lining the stomach is called
stomach cancer, also called gastric cancer. Stomach can-
cer is a polygenic disease with poor prognosis indicated
by several published literature [56]. A set of 11 miRNAs
are reported in the cancer-miRNA network that are dys-
regulated in stomach tumor tissue among which 10 are
significantly upregulated.Bandyopadhyay et al. Silence 2010, 1:6
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Brain and spinal tumors
Glioblastoma multiforme is the most malignant type of
astrocytoma, composed of spongioblasts, astroblasts and
astrocytes. It usually occurs in the brain but may occur in
the brain stem or spinal cord. MiR-21 is overexpressed in
glioblastoma tissues and cells and acts as an antiapoptotic
factor in cultured glioblastoma cells [57]. Twelve early
passage cultures from high grade gliomas and six glio-
blastoma cell lines (A172, U87, U373, LN229, LN428 and
LN308) were compared to non-neoplastic glial cells and a
variety of mammalian tissues. From the results miR-21
was found to be strongly overexpressed in the neoplastic
samples.
AIDS associated cancer kaposi's sarcoma
AIDS associated Kaposi's Sarcoma (KS) is the most com-
monly reported cancer in parts of Africa and it is increas-
ingly spreading out in other parts of the world where
HIV-1 infection is increasing day by day [58]. Kaposis sar-
coma-associated herpes virus (KSHV) is the causative
agent of Kaposi's Sarcoma and two B cell derived cancers
namely primary effusion lymphoma (PEL) and multi-
centric Castleman's disease [59-61]. Twelve miRNAs have
been identified in KSHV genome [62]. The hypothesis is
that the host/cellular genes targeted by KSHV encoded
miRNAs play a role in viral pathogenesis [63]. Thrombos-
pondin 1 (THBS1), that is known to be antiproliferative, a
protein inhibitor of angiogenesis, and a strong immune
stimulator that can regulate T cell migration through
extracellular matrix, is a potential target of multiple
KSHV miRNAs and is translationally repressed in the
presence of KSHV miRNAs like miR-k12-1, miR-k12-3-
3p and miR-k12-6-3p. It was predicted by miRanda to
have 34 binding sites for 12 KSHV miRNAs [64]. Down-
regulation of THBS1 can cause human cancer and may
aid in immune evasion of KSHV infected cells. S100A2
and PRG1 are two other target genes that are downregu-
lated in response to miRNAs and have link with cancer. A
recent study [63] provided a list of KSHV miRNA targets
but potential targets in all cell types such as lymphoid,
epithelial and endothelial cells, infected by KSHV are yet
to be discovered.
Esophageal cancer
A study regarding miRNA expression in esophageal can-
cer revealed that miR-203 and miR-205 have changed
expression in squamous cell carcinomas and esophageal
adenocarcinomas compared with normal squamous epi-
thelium. MiR-203 and miR-205 are also reported as
upregulated in lung cancer [30]. A predicted target of
miR-203 is the gene ECRG4 that has already been impli-
cated in esophageal cancer.
Involvement of miRNAs in patient's survival
It has been hypothesized that miRNAs have a deep corre-
lation with patient's survival. A report shows that the
expression level of Dicer is reduced in a fraction of lung
cancers and have a prognostic impact on the survival of
the surgically treated patients [65]. A univariate Cox pro-
portional hazard regression model with global permuta-
tion test in BRB-Array-Tools indicated that eight
miRNAs (miR-155, miR-17-3p, miR-106a, miR-93, let-7a-
2, miR-145, let-7b, and miR-21) were related to the ade-
nocarcinoma patients survival. Patients with high expres-
sion of either miR-155, miR-17-3p, miR-106a, miR-93 or
miR-21 and low expression of either let-7a-2, let-7b or
miR-145 were found to have a significantly worse progno-
sis. In [30], the survival analysis among the 41 stage I ade-
nocarcinoma patients revealed that three miRNAs (miR-
155, miR-17-3p, and miR-20) were associated with
patients survival. It has been observed in pancreatic can-
cer that high expression of miR-196a-2 and miR-219 can
cause of a lower survival of the patients (14.3 months and
13.6 months) than the low expression (26.5 months and
23.8 months) [38]. It is also anticipated that miRNAs may
act as potential diagnostic marker of specific cancer type.
An interesting observation is that in some cases miR-221
is not only overexpressed in papillary thyroid tumor tis-
sue but also overexpressed in normal thyroid tissue which
is adjacent to papillary thyroid carcinoma, suggesting that
this might be an important thyroid cancer marker. In
another investigation miR-99, miR-100, miR-100-1/2,
miR-125a, miR-125b-1, miR-199a-1 and miR-199a-2 are
overexpressed both in pancreatic cancer and chronic
pancreatitis compared with normal pancreatic tissue
indicating that these can be a common inciting event for
neoplastic growth [38].
Cancer-miRNA network
Several miRNAs are differentially expressed in various
cancers, suggesting common altered regulatory pathways.
Regulatory mechanisms of miRNAs can be well under-
stood by identifying functional modules of miRNAs and
their target mRNAs. It is known that if genes are associ-
ated with the same disorder they share common cellular
and functional characteristics and their protein products
have been shown to participate in the same cellular path-
way, molecular complex or functional module [66-68]. If
genes are linked with certain disorder associations, their
protein products should interact more likely with one
another within such disordered modules than with other
proteins [69]. In the same way we can hypothesize that if
the miRNAs are associated with the same cancer type
with similar dysregulation pattern, then their target genes
may share common cellular and functional characteris-
tics and the miRNAs may have common target onco/
tumor suppressor genes. Therefore, in order to globallyBandyopadhyay et al. Silence 2010, 1:6
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observe and identify the miRNAs and associated cancer
modules, generation of a cancer-miRNA network is cru-
cial.
The cancer-miRNA network model has been generated
based on the bipartite graph theoretic approach. We
formed a bipartite graph G = (U, V, E) where U is the set
of cancer types, V is the set of miRNAs and (u, v) ? E iff v
is differentially expressed or dysregulated in cancer type
u. In other words a bipartite graph based network model
is constructed consisting of two disjoint sets of nodes
where edges only exist between nodes from different sets.
Here U is a set of cancer types and V is a set of cancer
associated miRNAs. We have integrated an additional
information into our network model by associating 'solid'
or 'dotted' edges. A 'solid' edge means the miRNA is
upregulated in the associated cancer type whereas a 'dot-
ted' edge shows it's downregulation.
The complete network is provided in a tabular form in
(Additional file 1). Figure 1 shows a part of the cancer-
miRNA network for illustration. As is evident, a particu-
lar type of cancer may be associated with the dysregula-
tion of several distinct miRNAs and conversely
dysregulation of one miRNA can be associated with sev-
eral cancer types. The differential expression patterns of
experimentally verified human miRNAs in different can-
cer and normal tissue types obtained from extensive liter-
ature search are taken into account. Other relevant
parameters that have been considered are location of the
miRNAs at fragile sites and cancer associated genomic
regions, epigenetic alteration of miRNA expression and
abnormalities in miRNA processing target genes and pro-
teins.
Novel biological insights from the cancer-miRNA 
network
The Cancer-miRNA network shown in Additional file 1
throws up several new and interesting biological insights
which were not evident in individual experiments but
become evident when studied in the global perspective.
Tissue specific dysregulation patterns of miRNAs
Earlier it was believed that miRNAs are globally down-
regulated in tumor tissues [18]. However, current
research [21] shows that this may not be true. The cancer-
miRNA network also establishes that dysregulation pat-
terns of miRNAs may be both up as well as downregu-
lated. However, the cancer-miRNA network throws up an
interesting observation that dysregulation patterns of
miRNAs are tissue specific. A list of cancer types are
extracted from the network where a significant number
of miRNAs show either upregulation or downregulation
in that specific tissue type (see Table 1). For example, in
brain (central nervous system and glioblastoma) 94% of
the miRNAs (79/84) are downregulated (P = 7.106 × 10-
16, Fisher's exact test), and in hematogic, all the miRNAs
(32/32) are downregulated (P  = 1.642 × 10-8, Fisher's
exact test); on the other hand 91.3% of the miRNAs (42/
46) are upregulated in pancreatic cancer (P = 6.639 × 10-
13, Fisher's exact test) and all the miRNAs (9/9) are upreg-
ulated in lymphoma (P = 4.228 × 10-4, Fisher's exact test).
To illustrate this issue, we have considered individual
cancer types from the network and extracted the expres-
sion patterns of the associated miRNAs from the litera-
ture, these are included in Table 1. The terms such as
'deleted' or 'underexpressed' are considered as constitut-
ing the down regulation group, and terms such as 'ampli-
fied' or 'overexpressed' are considered as constituting the
upregulation group.
Hubs and cancer specific miRNAs
In Figure 1, it can be observed that several miRNAs act as
hubs, showing a significant dysregulation in several can-
cer types. One miRNA in the network is considered as
hub if the miRNA is dysregulated in significant number
of cancer types (here, five or more cancer types are con-
sidered,  P  < 10-16, randomization test). A hub miRNA
may show homogeneous or heterogeneous expression
pattern in multiple cancer types. Depending on the edges
pattern of homogeneous hub miRNA, the cancer-miRNA
network efficiently identify strong oncogenic or tumor
suppressor miRNAs. For example, miR-21 is upregulated
in all it's associated cancer types (except Hematologic)
and shows a strong oncogenic characteristic. In this arti-
cle, each cancer-miRNA link is validated by the experi-
mental evidence. For example, the link between miR-21
and cholangio carcinoma is established based on the sur-
vey of the following information from the literature. In
[70] miR arrays were performed on five primary cholan-
gio carcinomas and five normal bile duct specimens. Dif-
ferential expression of miR-21 in these 10 specimens was
verified by quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR). To validate these findings,
qRT-PCR for miR-21 was then performed on 18 addi-
tional primary cholangio carcinomas and 12 normal liver
specimens. MiR-21 was 95% sensitive and 100% specific
in distinguishing between cholangio carcinoma and nor-
mal tissues. As that of miR-21, miR-17-5p is overex-
pressed (shown with solid lines in Figure 1) in their
associated tumor types, showing strong oncogenic char-
acteristics. On the other hand let-7a-2 is downregulated
in all it's associated cancer types, showing a strong tumor
suppressor characteristic (shown in dotted lines in Figure
1).
In the network, a number of miRNAs are found that are
associated with ≤ 2 cancer types. These miRNAs can be
considered to be tissue specific. For a few miRNAs, evi-
dence of them being tissue specific in nature is available
in the literature. Though ≈100 miRNAs are identified asBandyopadhyay et al. Silence 2010, 1:6
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tissue specific miRNAs from the network, we anticipate
that for several of them, this may be due to a lack of
experimental evidence. As research is going on, these
miRNAs may also be associated with more number of
tumor tissues or cell lines and would not be recognized as
tissue specific miRNAs. A full list of possible tissue spe-
cific miRNAs, its expression patterns and associated
tumor types are shown in (Additional file 2).
Identification of cancer-miRNA module using 
computational approach for mining association
The Cancer-miRNA modules are extracted from the Can-
cer-miRNA network based on a computational technique
of mining associations between miRNAs and cancer
types. Association rule mining (ARM) is an important
tool to extract frequent patterns, associations or sub-
groups among sets of items from the data repository [71].
In this study, a comprehensive analysis of the combinato-
rial nature of miRNA dysregulation in cancer tissues has
been carried out by detecting rules that identify a set of
miRNAs dysregulated in several cancer types. For each
rule, the scope and the precision of the rule is measured
by the support and confidence statistics, respectively. To
limit the extraction of statistically significant association
rules, only the rules with support and confidence exceed-
ing a predefined minimum support and minimum confi-
dence threshold are extracted. In Table 2, the top five
rules are extracted with minimum support and confi-
dence of 0.3 and 0.8 respectively (P < 2.2 × 10-16, random-
ization test). However, in order to extract potential rules
the threshold needs to be set pretty low since, till date,
due to limited experimental validation each miRNA is
found to be dysregulated only in a few cancer tissue types.
As research is going on, more number of such rules are
expected to be observed with greater support and confi-
dence. In order to test the validation of our prediction,
Table 2: MiRNAs and associated cancer types in selected cancer-miRNA modules. 
Rule# Cancer-miRNA modules
miRNAs Cancer types 
(Dysregulation patterns)
Clustered miRNAs
1 {miR-100} ? {miR-125b} breast(D,D), cervical(D,D), 
HCC(U,U), lung(D,D), 
ovary(D,D), pancreas(U,U), 
uterus(U,U)
(miR-100, miR-125b)
2 {miR-125b, let-7a-2} ? {miR-21} breast(D,D,U), brain(D,D,U), 
hematologic(D,D,D), 
cervical(D,D,U), colon(D,D,U), 
lung(D,D,U), ovary(D,D,U)
(miR-125b, let-7a-2)
3 {miR-125a} ? {miR-125b} breast(U,D), brain (D,D), 
HCC(D,U), hematologic (D,D), 
lung(D,D), pancreas(U,U), 
uterus(U,U)
-
4 {miR-143} ? {miR-21} breast(D,U), brain (D,U), 
cervical(D,U), colon(D,U), 
hematologic(D,D), lung(D,U), 
pancreas(U,U), prostate(D,U), 
uterus(U,U)
-
5 {miR-143, miR-145} ? {miR-21, miR-125b} breast(D,D,U,D), 
colon(D,D,U,D), 
hematologic(D,D,D,D), 
lung(D,D,U,D), uterus(U,U,U,U)
(miR-143, miR-145)
6 {miR-17-5p, miR-20a} ? {miR-143, miR-145} colon(U,U,D,D), lung(U,U,D,D), 
prostate(U,U,D,D)
(miR-17-5p, miR-20a), (miR-143, miR-145)
7 {let-7a-1, let-7d, let-7f-1} ? {miR-17-5p} urothelial(D,D,D,U), 
colon(D,D,D,U), lung(D,D,D,U)
(let-7a-1, let-7d, let-7f-1)
8 {miR-101, miR-210} ? {let-7a-2} breast(D,U,D), lung(D,U,D), 
ovary (D,D,D)
-
In column 3, D = downregulated and U = upregulated for the corresponding miRNAs mentioned in column 2Bandyopadhyay et al. Silence 2010, 1:6
http://www.silencejournal.com/content/1/1/6
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including the top five rules, we have also extracted some
rules (bottom three rules in Table 2) from the network
that didn't meet the predefined cutoff values mentioned
above. Combining with the cancer-miRNA network data
set the obtained rules are then observed in a set of test
data set. The test data is a set of articles that were not
used in anyway to build the cancer-miRNA network or
are published after the submission of this article.
In each module a number of miRNAs are found that are
d y s r e g u l a t e d  i n  s e v e r a l  c a n c e r  t y p e s .  F o r  e x a m p l e ,  i n
module two, all the miRNAs are dysregulated in hemato-
logic, breast, brain, cervical, colon, lung and ovary. The
rule of this module depicts the fact that if miR-125b and
let-7a-2 are dysregulated in a cancer tissue or cell line
then miR-21 is also likely to be dysregulated in that can-
cer tissue (confidence = 1). A number of modules in Table
2 consists of at least one miRNA cluster (group of miR-
NAs that are located within 50 kb of genomic location
form miRNA cluster [72] or called neighboring miRNAs).
Earlier works provided us clues that neighboring miR-
NAs may be associated with the same disease [73] such as
cancer, cardiovascular disaese, Parkinson's disease, and so
on. However, it is unclear whether neighboring miRNAs
have differential coexpression patterns in a specific can-
cer tissue. In this regard, we observed the dysregulation
patterns of the miRNAs in the selected cancer tissues (see
Table 2). This clearly elucidates the fact that miRNAs
from the same cluster have the differential coexpression
patterns. For example, in module one (confidence = 1),
miR-100 and miR-125b are from the same cluster having
similar dysregulation patterns in breast, cervical, HCC,
lung, ovary, pancreas and uterus. In test data set also,
these two miRNAs are showing differential coexpression
patterns (in urothelial, both are upregulated). Analogous
observations are made for modules two to eight (see
Tables 2 and 3). In module two, miR-125b and let-7a-2
are from the same cluster and have downregulation in
seven cancer types, whereas miR-21 which is not in the
same cluster shows upregulation in six out of seven can-
cer types. In the test set, the clustered miRNAs are show-
ing differential coexpression pattern in HCC. In module
six, two miRNA clusters (miR-17-5p and miR-20a) and
(miR-143 and miR-145) are dysregulated in colon, lung
and prostate cancer tissues. Notable that intra cluster
miRNAs have shown similar dysregulation patterns in
these cancer tissues whereas inter cluster miRNAs have
the opposite expression patterns. In the test set, the intra
cluster miRNAs are showing differential coexpression
pattern in leukemia.
We then investigated dysregulation patterns of neigh-
boring miRNAs in all the cancer tissues. We found that
67% of the cancer types have at least two neighboring
miRNAs showing downregulation which is significantly
higher (P  < 10-7, Randomization test, for details see
Methods) than the randomly generated data set. A simi-
lar result is obtained for the neighboring miRNAs show-
ing upregulation in specific cancer type. We have also
measured the P values by varying the definition of cluster
(within 50 kb) and consistent result is obtained (P < 10-7,
Randomization test). These results elucidate the fact that
the neighboring miRNAs might be coexpressed in cancer
tissues as in normal tissue types.
Table 3: Validated cancer-miRNA modules
Rule # Cancer-miRNA modules
miRNAs Cancer types 
(Dysregulation patterns)
Clustered miRNAs
1 {miR-100}? {miR-125b} urothelial(U,U) [75]
2 {miR-125b, let-7a-2} ? {miR-21} HCC(D,D,U) [76]
4 {miR-143}? {miR-21} oral squamous cell carcinoma(D,U) [77]
4 {miR-143}? {miR-21} HCC(D,U) [76]
5 {miR-143, miR-145} ? {miR-21, miR-125b} oral squamous cell carcinoma(D,D,U,D) [77]
5 {miR-143, miR-145} ? {miR-21, miR-125b} prostate(D,D,U,D) [21,78-80]
5 {miR-143, miR-145} ? {miR-21, miR-125b} HCC(D,D,U,D) [76]
6 {miR-17-5p, miR-20a} ? {miR-143, miR-145} leukemia(U,U,D,D) [81,82]
8 {miR-101, miR-210} ? {let-7a-2} colon(D,U,D) [83-85]
8 {miR-101, miR-210} ? {let-7a-2} prostate(D,U,D) [83,86]
8 {miR-101, miR-210} ? {let-7a-2} melanoma(D,U,D) [42,83,84,87]
8 {miR-101, miR-210} ? {let-7a-2} HCC(D,U,D) [76]Bandyopadhyay et al. Silence 2010, 1:6
http://www.silencejournal.com/content/1/1/6
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Characteristics of a typical cancer-miRNA module
It has been observed that miR-32, miR-29b-2, miR-21,
miR-20a, miR-191, miR-17-5p, miR-106a, miR-155 and
miR-24-2 all have significant dysregulation in lung, colon
and pancreatic cancer cell line. Thus they can be consid-
ered to form a cancer-miRNA module as shown in Figure
2. Among these, the first seven miRNAs also have a sig-
nificant dysregulation in prostate tumor tissue but inter-
estingly no relationship between prostate tumor and
miR-155 and miR-24-2 is known. However, from the net-
work it appears likely that these two miRNAs might be
implicated in prostate tumor. This observation makes it
imperative to investigate the expression pattern of miR-
155 and miR-24-2 in prostate cancer cell line.
We also investigated whether the miRNAs involved in
the module shown in Figure 2 have common target onco/
tumor suppressor genes. As shown in Table 4 we found
that most of the miRNAs in the module have some com-
mon predicted target onco/tumor suppressor genes. For
example, APC is involved in colon and pancreatic cancer
and it is a predicted target of miR-17-5p, miR-32, miR-
20a and miR-106a. EP300 is involved in colon and pan-
creatic cancer (predicted target of miR-17-5p, miR-32,
miR-20a and miR-106a), and so on. Beside these common
target genes, we also found a number of potential target
genes for each of the miRNAs that clearly shows the
involvement of these miRNAs in the four cancer types,
mentioned in the module. For example, TCF7L2, NRAS,
VEGF and HOXC8 are the target genes of miR-191 which
are involved in colon, lung, pancreatic and prostate can-
cer respectively. Some prostate cancer causing target
genes for miR-155 such as PTGER2, MSH2 and VIM sug-
gests the involvement of miR-155 in prostate cancer.
These target onco/tumor suppressor genes of miR-155
indicates the possibility of dysregulation of miR-155 in
prostate cancer cell line. This suggests a combinatorial
effect of the module associated miRNAs on target gene
regulation in selective cancer tissues or cell lines.
Another important observation from Figure 2 is that all
the miRNAs except miR-155 and miR-24-2 are overex-
pressed in colon, pancreatic and prostate cancer. Except
miR-29b-2 (which is down regulated) and miR-32 (which
is deleted), these are also overexpressed in lung cancer.
This might suggest further experimentation with miR-
29b-2 and miR-32 to either establish or correct this
observation. These information could be helpful for fur-
Hubs of the network
Figure 1 Hubs of the network. Solid edge = overexpression/amplification, dotted edge = underexpression/deletion.Bandyopadhyay et al. Silence 2010, 1:6
http://www.silencejournal.com/content/1/1/6
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ther research on the implication of miRNAs in cancer. As
the amount of evidence of the involvement of human
miRNAs in cancer grows day by day, the utility of such a
cancer-miRNA network will be more evident in future.
Conclusions
Recent evidence indicates that miRNAs have important
roles in human malignancies and act as onco/tumor sup-
pressor miRNAs. The cancer associated genomic regions,
putative and experimentally verified target onco/tumor
suppressor genes, significant over or underexpression of
the miRNAs in specific cancer tissues or cell lines are a
few potential evidences of the involvement of miRNA in
cancers. In this article an indepth survey has been con-
ducted on the dysregulation of specific miRNAs in differ-
ent cancers. This leads to the development of a cancer-
miRNA  network that provides a global perspective on
which miRNAs are dysregulated in which cancer type as
well as the pattern of dysregulation, namely, upregulation
or downregulation. Beside this, the network (Additional
file 1) also provides miRNA's chromosomal location with
start and end points, technique used to measure the
expression level, fold change, P-value, cancerous samples
and cell lines used in the experiment, non-cancerous
samples and cell types, article references and pubmed ids.
The  cancer-miRNA  network throws up several useful
information such as, showing several cancer types and its
associated miRNAs, identifying the miRNAs that act as
hubs or those that are cancer specific. A number of hub
miRNAs are also identified from the network that have a
strong oncogenic or tumor suppressor characteristics,
and so on. Analysis of cancer associated miRNAs based
on the proposed network architecture revealed the fact
that miRNAs dysregulation patterns are highly tissue
dependent. A number of cancer types have been identi-
fied where a significant number of miRNAs are either
upregulated or downregulated (see Table 1). The cancer-
miRNA modules obtained from the cancer-miRNA net-
work have been identified based on a computational
technique of mining associations between miRNAs and
cancer types. The miRNAs in a cancer-miRNA module
depicts the fact that these miRNAs might have a chance
to be combinatorially dysregulated in selected cancer tis-
sues or cell lines. An interesting observation is that the
neighboring miRNAs in a cancer-miRNA  module may
have similar dysregulation patterns in the associated can-
Cancer-miRNA module
Figure 2 Cancer-miRNA module. Solid edge = overexpression/amplification, dotted edge = underexpression/deletion, blue dotted edge = un-
known.Bandyopadhyay et al. Silence 2010, 1:6
http://www.silencejournal.com/content/1/1/6
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cer types. This observation is validated by reporting 12
such examples extracted from the test data set (see Table
3).
Limited work has been done towards revealing the fact
that a number of miRNAs can control commonly altered
regulatory pathways. However, this becomes immediately
evident by accompanying the analysis of cancer-miRNA
relationships in the proposed bipartite graph based net-
work model. The importance of this network is multidi-
mensional and raises many unaddressed questions, for
example, miR-155 and miR-24-2 may be implicated in
prostate cancer though such a relationship is not yet
experimentally revealed. Determination of the combina-
torial effects of dysregulated miRNAs in specific cancer
type is still not uncovered due to the lack of knowledge
on existing cancer-miRNA  modules and it's associated
common target onco/tumor suppressor genes. In this
network model several cancer types have been identified
where almost all the miRNAs are either upregulated or
downregulated. This might be considered as an interest-
ing research area for the researchers to discover the exact
biology behind this interesting event. These observations
are expected to have an intense implication in cancer and
may be useful for further research.
Methods
Rule extraction
The association rule mining (ARM) algorithm Apriori
[74] is used in order to extract the potential rules from
the  cancer-miRNA  network. The ARM algorithm is
decomposed into two subtasks namely (1) frequent item-
set (miRNAs) generation and (2) rule generation. In the
ARM: Itemset: Set of miRNAs (for example, A, X, Y, Z).
Support of an Itemset: Number of transactions that
contains the itemset.
Frequent itemset: Itemset with support ≥ a threshold.
Confidence of a rule X ? Y provides an estimate of the
conditional probability of Y given X. The probability is
taken as observed frequency. The formal definitions of
confidence and support are the following
Conf X Y
times Y and X appear together
times X appears
()
#
#
, →=
(1)
Supp X Y
times Y and X appear together
transactions
()
#
#
. →=
(2)
Table 4: Predicted common target onco/tumor suppressor genes involved in four types of cancer. 
Target onco/tumor 
suppressor genes
Type of cancer
Colon lung pancreas prostate
APC 17-5p, 32, 20a, 106a 17-5p, 32, 20a, 106a
EP300 17-5p, 32, 20a, 106a 17-5p, 32, 20a, 106a
DNMT1 17-5p, 32, 106a
MSH3 17-5p, 20a, 106a
RB1 17-5p, 20a, 106a
HOXB4 17-5p, 20a, 106a
RECK 21, 106a, 155
ETV1 17-5p, 20a,106a
SYT7 17-5p, 20a,106a
EGR1 191, 32, 106a
PTEN 17-5p, 21, 20a,106a
MCL1 17-5p, 32, 20a,106a
STAT3 17-5p, 21, 20a,106a
Table should be read in this way: APC is a target gene of miR-17-5p, miR-32, miR-20a and miR-106a and this gene is involved in colon and 
pancreatic cancerBandyopadhyay et al. Silence 2010, 1:6
http://www.silencejournal.com/content/1/1/6
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Find all association rules R in the cancer-miRNA net-
work such that Supp(R) ≥ S (a minimal support threshold)
and Conf(R) ≥ C (a minimal confidence threshold).
In Apriori, finds out all the frequent itemsets that are
above the support threshold. The property of the Apriori
algorithm is that, every subset of a frequent itemset is fre-
quent and every superset of an infrequent itemset is
infrequent. In Apriori, finds frequent itemsets of length k
f r o m  fr eq u e n t  i t e m s e ts  o f  l e n gt h  k  - 1. If itemset I  of
length k - 1 is not frequent, then itemset I' of length k can-
not be frequent, if I is a subset of I'. Hence this branch can
be pruned. The steps of the first task, that is, frequent
itemset generation are:
1. C1 = set of all 1-large frequent itemsets (>S)
2. k = 1
3. F ind frequent itemset, Lk, from Ck, the set of all
candidate itemsets
4. Form Ck+1 from Lk
5. k = k + 1
6. Repeat 3 to 5 until Ck is empty
7. Return ? Lk
In rule generation, initially all the high confidence rules
t h a t  h a v e  o n l y  o n e  i t e m  i n  t h e  r u l e  c o n s e q u e n t  a r e
extracted. These rules are then used to generate new can-
didate rules. For example, if {XYZ} ? {A} and {AXY} ? {Z}
are high confidence rules, then the candidate rule {XY} ?
{AZ} is generated by merging the consequent of both the
rules.
Statistical analysis
To show the cancer tissue specific dysregulation patterns
of miRNAs we used Fisher's exact test performed in the
statistical platform R. The two dimensional contingency
matrix consists of the experimental data set and the back-
ground data set. From the network, a number of upregu-
lated and downregulated miRNAs obtained from the
specific cancer tissue type are considered as the experi-
mental data set. Rest of all the up and downregulated
miRNAs from all the cancer types (except the one used in
experimental data set) are considered as background data
set.
A randomization test is performed for all the hub miR-
NAs by edge swapping procedure between cancer and
miRNA such that the degree of each cancer type is pre-
served. Randomization test is performed 1,000 times and
reject the null hypothesis that the randomized data is
greater than the observed value at the 5% significance
level. Similarly, for modules, each module is considered
separately and the P value is measured by performing a
randomization test. During randomization again the
degree of each cancer type is preserved.
Network visualization
The  cancer-miRNA  network is visualized by publicly
available tool Pajek
http://vlado.fmf.uni-lj.si/pub/networks/pajek/
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